TY - JOUR T1 - Lower DNA methylation levels in CpG island shores of <em>CR1, CLU</em>, and <em>PICALM</em> genes in the blood of Alzheimer’s disease patients JF - medRxiv DO - 10.1101/2020.03.14.20035683 SP - 2020.03.14.20035683 AU - Risa Mitsumori AU - Kazuya Sakaguchi AU - Shumpei Niida AU - Nobuyoshi Shimoda Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/17/2020.03.14.20035683.abstract N2 - The aim of the present study was to (1) investigate the relationship between late onset AD and DNA methylation levels in the top six Alzheimer’s disease (AD)-related genes in blood and (2) examine its applicability to the diagnosis of AD. We examined methylation differences at CpG island shores in the top six genes using Sanger sequencing, and one of two groups of 48 AD patients and 48 elderly controls was used for a test or replication analysis. We found that methylation levels in three out of the six genes, CR1, CLU, and PICALM, were lower in AD subjects. The combination of CLU methylation levels and the APOE genotype classified AD patients with AUC=0.84 and 0.80 in the test and replication analyses, respectively. Our results implicate methylation differences at the CpG island shores of AD-related genes in the onset of AD and suggest their diagnostic value.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by The Research Funding for Longevity Sciences (26-16 and 29-20) from National Center for Geriatrics and Gerontology.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe make all data underlying the findings described in our manuscript fully available without restriction. ER -